Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in Italy
30 open options
- TRIALPHASE4RECRUITING
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
creon 35.000 Ph.U (R) · Best Standarard of Care — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- TRIALNARECRUITING
Pancreatic Cancer Evolution Upon Treatment
Fine Needle Biopsy or Aspiration — 1 site
- TRIALNARECRUITING
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
percutaneous, laparoscopic or laparotomy lesion electrochemotherapy — 1 site
- TRIALNARECRUITING
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas — 2 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 66 sites
- TRIALPHASE1RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
LY4170156 · bevacizumab · carboplatin — 23 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101 · Nab-paclitaxel · Gemcitabine — 93 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALNANOT_YET_RECRUITING
PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)
Clostridium butyricum CBM588 Strain · Placebo — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma
RR001 — 1 site
- TRIALNARECRUITING
Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy
removal of para-aortic lymphnodes (PALN) — 1 site
- TRIALPHASE2RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
BAY2927088 — 54 sites
- EXPANDED ACCESSAVAILABLE
Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer
Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS) — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sacituzumab tirumotecan · Fluorouracil (5-FU) · Leucovorin (LV) or levoleucovorin — 55 sites
- TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 86 sites
- TRIALPHASE2RECRUITING
Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver
Surgical resection of both the primary tumor and liver metastases — 1 site
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
- TRIALPHASE3RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine · Placebo — 67 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALNARECRUITING
Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus).
use of PancreasPlus app — 2 sites
- TRIALNARECRUITING
Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
DaRT seeds insertion — 1 site
- TRIALNARECRUITING
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Functional tests · Multi-omics analyses · Cytogenetics/ FISH — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Risvutatug Rezetecan · Drug 1 · Drug 2 — 85 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ifinatamab deruxtecan — 120 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.